Plus   Neg

Vertex's TRIKAFTA Accepted For Priority Review By Canada For Treatment Of Cystic Fibrosis

Vertex Pharmaceuticals Inc. (VRTX) said Monday that its New Drug Submission for TRIKAFTA is accepted for Priority Review by Health Canada. TRIKAFTA is the company's investigational triple combination medicine for the treatment of cystic fibrosis in people ages 12 years and older.

Following the acceptance of Priority Review, the conventional review timeline of 300 days is reduced to 180 days. The expected approval target by Health Canada is in the first half of 2021.

Cystic fibrosis is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide.

Cystic fibrosis is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. Cystic fibrosis is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Resorts developer and operator Las Vegas Sands Corp. (LVS) announced Wednesday that it has entered into definitive agreements to sell its Las Vegas real property and operations, including The Venetian Resort Las Vegas and the Sands Expo and Convention Center for an aggregate purchase price of approximately... Carmaker Stellantis N.V., created with the merger of Fiat Chrysler Automobiles N.V. and France's Peugeot S.A., on Wednesday announced individual fiscal 2020 results for both the companies. FCA and PSA recorded sharply lower profit and revenues in the year. However, FCA 's fourth quarter adjusted operating margin improved from last year. Stellantis also announced a dividend as agreed on the merger The restaurant industry continues to struggle in pandemic conditions with January consumer spending in restaurants well below pre-pandemic levels, according to new data released by the National Restaurant Association or NRA. Despite the slowdown in COVID-19 outbreaks and the increased distribution of vaccines, most restaurant operators do not expect a return-to-normal business conditions any time.
Follow RTT